CIK 0001811063 · Non-accelerated filer<br>Smaller reporting company
Nuvation Bio Inc.
Sign in to watch- Ticker
- NUVB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850862255
- Phone
- 332-208-6102
- Business address
- 1 PENNSYLVANIA PLAZA, SUITE 3805, NEW YORK, NY, 10019
- Former names
- Panacea Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $709,240
- in 1 filing, $709K under 10b5-1 plans
Net −$709,240. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-18 | Markel Stacy CHIEF PEOPLE OFFICER | Purchase | +10,000 | $1.71 | $17K | 29,591 |
| 2025-06-17 | Sauvage Philippe Chief Financial Officer | Purchase | +4,000 | $1.79 | $7K | 9,902 |
| 2025-06-16 | Sauvage Philippe Chief Financial Officer | Purchase | +3,300 | $1.84 | $6K | 5,902 |
| 2025-06-16 | Sjogren Colleen Chief Commercial Officer | Purchase | +50,000 | $1.81 | $90K | 81,000 |
| 2025-06-16 | Wentworth Kerry CHIEF REGULATORY OFFICER | Purchase | +26,000 | $1.79 | $47K | 26,000 |
| 2025-06-16 | Wentworth Kerry CHIEF REGULATORY OFFICER | Purchase | +24,000 | $1.80 | $43K | 50,000 |
| 2025-06-16 | Hung David PRESIDENT AND CEO | Purchase | +500,000 | $1.79 | $894K | 59,281,054 |
| 2025-05-21 | VERNON W ANTHONY Director | Grant or award · Stock Option (Right to Buy) | +292,983 | 292,983 | ||
| 2025-05-21 | Mashal Robert Director | Grant or award · Stock Option (Right to Buy) | +292,983 | 292,983 | ||
| 2025-05-21 | FALBERG KATHRYN E Director | Grant or award · Stock Option (Right to Buy) | +292,983 | 292,983 | ||
| 2025-05-21 | BLICKENSTAFF KIM D Director | Grant or award · Stock Option (Right to Buy) | +292,983 | 292,983 | ||
| 2025-05-21 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +292,983 | 292,983 | ||
| 2025-05-02 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +20,000 | $1.94 | $39K | 32,000 |
| 2025-05-02 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale 10b5-1 | −20,000 | $2.50 | $50K | 12,000 |
| 2025-05-02 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | $1.94 | $39K | 480,000 |
| 2025-04-07 | Hung David PRESIDENT AND CEO | Purchase | +300,000 | $1.63 | $488K | 58,781,054 |
| 2025-04-04 | Hung David PRESIDENT AND CEO | Purchase | +200,000 | $1.66 | $333K | 58,481,054 |
| 2025-04-01 | Mashal Robert Director | Purchase | +1,100 | $1.67 | $2K | 101,100 |
| 2025-04-01 | Mashal Robert Director | Purchase | +98,900 | $1.67 | $165K | 200,000 |
| 2025-02-28 | Wentworth Kerry CHIEF REGULATORY OFFICER | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 |
Page 5 of 15 · 291 trades